Vera Therapeutics

Kidneys
#Clinical trial #Kidney disease #Nephrology #Takeda #Vera Therapeutics

Positive news for IgAN treatment presented at Kidney Week

Positive data from two trials in immunoglobulin A nephropathy (IgAN) were shared at the American Society of Nephrology Kidney Week 2024 in San Diego, California. Vera Therapeutics announced data from its ORIGIN Phase IIb trial of atacicept that showed stabilised kidney function through 96 weeks of… Read More

#News #Trending News

Clinical trial
#Autoimmune disease #Clinical trial #Phase II trial #Vera Therapeutics

Drug shows disease-modifying effect in IgA nephropathy

Vera Therapeutics has announced positive 72-week data from the open label extension (OLE) period of its Phase IIb ORIGIN clinical trial of atacicept in participants with IgA nephropathy (IgAN). In aggregate, the 72-week data with atacicept are consistent with a profile of true disease modification in… Read More

#News